{"name":"Allist Pharmaceuticals, Inc.","slug":"allist-pharmaceuticals-inc","ticker":"","exchange":"","domain":"allist.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-02-15","label":"Alflutinib Phase 3 readout (Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer)","drug":"Alflutinib","drugSlug":"alflutinib","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-12-31","label":"Alflutinib Phase 3 readout (Advanced or Metastatic Non-small Cell Lung Cancer)","drug":"Alflutinib","drugSlug":"alflutinib","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-09-01","label":"Alflutinib Phase 3 readout (NSCLC Patients With Brain Metastasis)","drug":"Alflutinib","drugSlug":"alflutinib","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-01-01","label":"Alflutinib Phase 3 readout (Non-small Cell Lung Carcinoma)","drug":"Alflutinib","drugSlug":"alflutinib","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-12-01","label":"Alflutinib Phase 3 readout (Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer)","drug":"Alflutinib","drugSlug":"alflutinib","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Firmonertinib Mesilate Tablets","genericName":"Firmonertinib Mesilate Tablets","slug":"firmonertinib-mesilate-tablets","indication":"Non-small cell lung cancer with EGFR mutations including T790M resistance mutations","status":"phase_3"},{"name":"Furmonertinib Mesilate Tablets","genericName":"Furmonertinib Mesilate Tablets","slug":"furmonertinib-mesilate-tablets","indication":"Non-small cell lung cancer with EGFR mutations, including T790M resistance mutations","status":"phase_3"},{"name":"JAB-21822","genericName":"JAB-21822","slug":"jab-21822","indication":"FGFR-driven solid tumors (Phase 3 development)","status":"phase_3"},{"name":"JAB-3312","genericName":"JAB-3312","slug":"jab-3312","indication":"FGFR-altered solid tumors (Phase 3 development)","status":"phase_3"},{"name":"Pemetrexed Disodium for Injection","genericName":"Pemetrexed Disodium for Injection","slug":"pemetrexed-disodium-for-injection","indication":"Metastatic non-small cell lung cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"AST2818 Tablets","genericName":"AST2818 Tablets","slug":"ast2818-tablets","indication":"Other","status":"phase_1"},{"name":"Alflutinib","genericName":"Alflutinib","slug":"alflutinib","indication":"Other","status":"discontinued"},{"name":"Furmonertinib 240mg","genericName":"Furmonertinib 240mg","slug":"furmonertinib-240mg","indication":"Other","status":"phase_1"},{"name":"[14]-AST2818","genericName":"[14]-AST2818","slug":"14-ast2818","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Firmonertinib Mesilate Tablets","genericName":"Firmonertinib Mesilate Tablets","slug":"firmonertinib-mesilate-tablets","phase":"phase_3","mechanism":"Firmonertinib mesilate is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations.","indications":["Non-small cell lung cancer with EGFR mutations including T790M resistance mutations"],"catalyst":""},{"name":"Furmonertinib Mesilate Tablets","genericName":"Furmonertinib Mesilate Tablets","slug":"furmonertinib-mesilate-tablets","phase":"phase_3","mechanism":"Furmonertinib is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations.","indications":["Non-small cell lung cancer with EGFR mutations, including T790M resistance mutations"],"catalyst":""},{"name":"AST2818 Tablets","genericName":"AST2818 Tablets","slug":"ast2818-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Alflutinib","genericName":"Alflutinib","slug":"alflutinib","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Furmonertinib 240mg","genericName":"Furmonertinib 240mg","slug":"furmonertinib-240mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JAB-21822","genericName":"JAB-21822","slug":"jab-21822","phase":"phase_3","mechanism":"JAB-21822 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation.","indications":["FGFR-driven solid tumors (Phase 3 development)"],"catalyst":""},{"name":"JAB-3312","genericName":"JAB-3312","slug":"jab-3312","phase":"phase_3","mechanism":"JAB-3312 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling.","indications":["FGFR-altered solid tumors (Phase 3 development)"],"catalyst":""},{"name":"Pemetrexed Disodium for Injection","genericName":"Pemetrexed Disodium for Injection","slug":"pemetrexed-disodium-for-injection","phase":"phase_3","mechanism":"Pemetrexed is a folate antagonist that inhibits multiple enzymes involved in nucleotide synthesis, disrupting DNA and RNA production in cancer cells.","indications":["Metastatic non-small cell lung cancer","Malignant pleural mesothelioma","Locally advanced or metastatic urothelial cancer"],"catalyst":""},{"name":"[14]-AST2818","genericName":"[14]-AST2818","slug":"14-ast2818","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQak9WbS1GQ3JuTDJjbGMyX3dEdjVmc09JTVFfc3g3WGJYX1NZY183RVhoR0xCTlVROVNWd0UtNlAwMzZUb09lZEk2bXEtd3lzNWU5bG9kQnE3ZlFLRFM1UGNDMU1ubVJqcWVuVUhjYkhtdjQ1UFQ4SkNfcXJ3WjRHNm04c0pCYjVKMGFaWUtKSkloaVJRcjZWMlpneEJYNkNVZmhYZlFpYUVKSzdvX0JYTllESDJZdF9HQ1E?oc=5","date":"2026-03-19","type":"earnings","source":"Sahm","summary":"Jacobio Pharma Poised To Turn A Profit From Precision Cancer Drugs - Sahm","headline":"Jacobio Pharma Poised To Turn A Profit From Precision Cancer Drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNcDRUdktlWHljR3FtVlNOT3JHS2gtMzNMaXNuQzBBX3ctNjdyd21hNzE3TFhrb2xFVkVLd3lzRXhhYUlCNk1CVkRhQ2twdWdnRkNJYXRxa1ZwOWNqMGZ0UUp0WjZpTkoyNzRWeVZWTnZRSk05S3dhdmZwTmVRQ2tFNFpKNTRZMjVDd2xIVHdOWks2Sl9hU2l3NjZhTXNYSzBxREhwMEtUOA?oc=5","date":"2025-12-22","type":"pipeline","source":"Fierce Biotech","summary":"AstraZeneca fronts $100M for Jacobio's clinical-stage pan-KRAS inhibitor - Fierce Biotech","headline":"AstraZeneca fronts $100M for Jacobio's clinical-stage pan-KRAS inhibitor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPU3l3UE9sNmRLR0xMdVNUejVGU2FhUUROSFBvdHFfZ3BXQVlmV01NSFlfZ3l4VDl2N0dqVVUwS3BHMTVhSlJOLWlRdWNwdjJGMzd2MFB6eVl6d0hGS2RKNGRNWDktS293OUJGRTlENDY5Qjk1YjhZR203LXdhcXhUMlJ3cVU?oc=5","date":"2025-06-23","type":"trial","source":"Oncology Pipeline","summary":"ArriVent goes Further into PACC mutations | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"ArriVent goes Further into PACC mutations | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOUS1FV3pkd0ZBZkhKSS1jSlF5REEtNjRNZDZOX3VzX20tZEU3VUxTVmRHbm92RG9lb1hTOVlGMHJWSzhhalRzS19teXNPNndEbGNrLXhMMmZyeHM3ZmlrZGJzaU5VeWZ3VHBrWEl1WlBjbUYyVi1WdEVyQ0pMcm9xeTBB?oc=5","date":"2024-09-02","type":"pipeline","source":"Pharmaceutical Technology","summary":"Jacobio Pharma grants Allist rights to two assets in China - Pharmaceutical Technology","headline":"Jacobio Pharma grants Allist rights to two assets in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNcmVSNlRST0hraTlkMW9qVGdpMmVHQ1lQb1JSZGZFcGRZOWZmZ2owbE03eThpUFdZcnNuNklXX0V3QUVEeVEzbnF2c3R6R01yNnlJWklBUDBJT0hhdVpZa1RJcFVfdHZ1YXhpbW01MEZidHNFN19HQWZmV0NWa1NJcWtXUm95Njc0dmlFZk92UVBsUURrb2dyZ21RUnBLbmtjRkJjMzRuOFlENEtzWlN5Q1JCS0xBX2lSSi1pTENtYXpOb1RMeFZlN3ZnOFh2MDhZZXpYRGRja20zYnNzbkJrUmczUUF5Wks3WFE?oc=5","date":"2024-08-30","type":"deal","source":"PR Newswire","summary":"Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China - PR Newswire","headline":"Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxNRlNWckdWUmh4QkdKZldQOFk1WEVjVGVsc0t5dm1hUjRxcGJ6UEl4azVkMzF4a2t6SVM2SHRESjI5encybHJsSF9JQ0dDMkJUMUF0dEN6Zm5EY01xVW1qby00TUZ0eGtIZElrTzRNR3Q5NWhIZ3dHTWY3T01sMnlUUDEzN1FZbWlYM3c5RGRiaEctalJhTTYzSEIwbzBsTHZjZ0FOeWNobWlkU2xncXJicjRmYW5nRWlLU1FXMWhPRGE0b3U5RE9zSXFEeUptZEVZQXlhOTZkdUVRNFA2Y1lyaUY2NEJaOFNqS1pEWWxNOF9hSUhKU0lRakoxT3FKQ0h0X0otNE5HVkw4cFhsQXFkM1hTb0VLYUlVdUxsdlRCS1J6ZDgyMFBQRXpFblJxdzJo?oc=5","date":"2023-09-10","type":"pipeline","source":"GlobeNewswire","summary":"Allist and ArriVent Announce Interim Results from Ongoing - GlobeNewswire","headline":"Allist and ArriVent Announce Interim Results from Ongoing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE9BbUxSUUQwWVJFNHhiSEljbHRQaHhVNXJmU2NnT1BrUnhSWDJIdFFIUG1EdHlmelJHbEY5eGx5aG9ZTDAwMmRqX1ZYc0J1VGpEck1SSXN4WTgyR0VBMEp6WnpGYUJOcmZpRHRlcw?oc=5","date":"2023-03-02","type":"deal","source":"팜뉴스","summary":"Abbisko Therapeutics Announces an Out-License Agreement with Allist for ABK3376 - 팜뉴스","headline":"Abbisko Therapeutics Announces an Out-License Agreement with Allist for ABK3376 - 팜뉴스","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPbmdWcXRkVDcxU2hvQ0d2YnFQZGtFb0hqaW01bTY4VWZPaEdjWjlQQXNocWNSdWpFck5SUk1kd3hKME9mZWhMRUdWaVNHZXZrZkpxeTVjZUstdjlXV0dNbE5SVTljcmlOeXFRcDFNLVRoSWhyenhNQ3JDWXpFRDQ0MmlWT05mSjVKR3pLQ1FTSENabXJlNHNhQnVnMEhKZXhyVjVEaA?oc=5","date":"2022-05-20","type":"pipeline","source":"BioWorld News","summary":"Acea Pharma fails to win green light for abivertinib in China - BioWorld News","headline":"Acea Pharma fails to win green light for abivertinib in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQY3VITUtyX21ia3M5bEQxcHJtc0ZZRlJhck1zZ0x6VGNNSXBqZmxXcmNjZ0Q1RHpGLWw5SUc5V1Y3cHp5bUNxZW9VUktWc3Q3Z2Jya1NsWEh6eG1CSjRVTWFLRno2SlJTUHdoOGVSLVNOSU5FYnE5ZFo2TnJWbUtkY3pWNUUzVWZjUmpObmROMlQzb0piU0U0REZON1drVFJfcnN3NUV3T0tiZGY0M1E?oc=5","date":"2021-06-30","type":"pipeline","source":"MedCity News","summary":"After a $3B exit, a biopharma veteran unveils a new company and a global focus - MedCity News","headline":"After a $3B exit, a biopharma veteran unveils a new company and a global focus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxOTGg2V1NhRUk0Qk53a2Z0Z2hEOFZkZXhkUUU4dk9HZzZ6T2prVjhVRXFQOGN1aHl5TmJBZUpfdzJxYVVzQ2FOa3JlMTlqdEpia1d5SmN5dTFCVnlKM2g5Y0lWNHFKU2lzb2daakZWZ295Q1h6WnFZcXhrN3pGN1k0dExRUUh4VUtMRzBqQWhBLUJjeDZ2MzFqdGVOWUdsTjRsV3J3MUFDQTZwT3JTNmR0bUVWYTRMRVUtcmdnWUhoTjdJMXFxdzFCaW10OFg1QXppeE9pai1oc2xnVWV6em9sNEl5QmhhQ3dsbGNPd3BRV2xKQ1RKdWtiRHBXVGEyRHg1djFsYUtob3JENUpTTVZQREJKQUk0ekhEUTJ6U2ZLcEhMZjBVdjJIM1VXeE9Cdw?oc=5","date":"2021-06-30","type":"pipeline","source":"GlobeNewswire","summary":"ArriVent Biopharma Launches with Up To $150M in Series A - GlobeNewswire","headline":"ArriVent Biopharma Launches with Up To $150M in Series A","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"phase_3":5,"phase_1":3,"discontinued":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}